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Abstract
Benzalkonium chloride (BAC) is the most common preservative in ophthalmic preparations. Here, we investigated the
corneal alternations in rabbits following exposure to BAC. Twenty-four adult male New Zealand albino rabbits were
randomly divided into three groups. BAC at 0.01%, 0.05%, or 0.1% was applied twice daily to one eye each of rabbits for 4
days. The contralateral untreated eyes were used as control. Aqueous tear production and fluorescein staining scores of
BAC-treated eyes were compared with those of controls. The structure of the central cornea was examined by in vivo
confocal microscopy. Expression of mucin-5 subtype AC (MUC5AC) in conjunctiva was detected by immunostainig on
cryosections. Corneal barrier function was assessed in terms of permeability to carboxy fluorescein (CF). The distribution and
expression of ZO-1, a known marker of tight junction, and reorganization of the perijunctional actomyosin ring (PAMR) were
examined by immunofluorescence analysis. Although there were no significant differences between control and BAC-
treated eyes in Schirmer scores, corneal fluorescein scores and the number of conjunctival MUC5AC staining cells, in vivo
confocal microscopy revealed significant epithelial and stromal defects in all BAC-treated corneas. Moreover, BAC at 0.1%
resulted in significant increases in central corneal thickness and endothelial CF permeability, compared with those in control
eyes, and endothelial cell damage with dislocation of ZO-1 and disruption of PAMR. Topical application of BAC can quickly
impair the whole cornea without occurrence of dry eye. A high concentration of BAC breaks down the barrier integrity of
corneal endothelium, concomitant with the disruption of PAMR and remodeling of apical junctional complex in vivo.
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Introduction
Preservatives are a major component of the ophthalmic prepara-
tions to provide antimicrobial activity and prevent decomposition of
the active drug in multi-dose bottles. Benzalkonium chloride (BAC) is
the most common preservative in ophthalmic preparations for its
apparently good safety/efficacy profile [1]. Furthermore, as a soluble
antimicrobial agent and cationic surfactant, BAC was found to have
ability to enhance penetration of active compounds [2,3]. However, a
large number of experimental and clinical studies have shown that
long-term use of topical drugs with BAC may induce ocular surface
changes, causing ocular discomfort, tear film instability, loss of goblet
cells, inflammation, conjunctival squamous metaplasia, epithelial
apoptosis, subconjunctival fibrosis and the potential risk of failure
for further glaucoma surgery [1].
BAC is most often used at a concentration of 0.01% (ranging
from 0.004% to 0.02%) in ophthalmic preparations [4]. As long-
term clinical testing with low concentration of BAC is difficult to
conduct on animals [5], many researchers have investigated acute
toxic effects of high concentrations of BAC (approximately 1-50
times the commercial concentrations) on the ocular surface. In
1944, Swan found that BAC causes punctuate disturbances to
corneal epithelium at concentration of 0.04%, and edema and
cellular desquamation with corneal lesions at a concentration of
0.1% [6]. Since then, much clinical and experimental evidence has
been obtained to support the notion that the toxic effect of BAC on
the ocular surface is primarily related to its concentration. Recently,
Liang et al. showed that following short- and repeated exposure to
0.02% BAC, a large number of inflammatory cells were present in
rabbit corneal epithelial basal layer and stroma [7]. Although a few
studies have proven that topical application of high concentration of
BAC (0.25% or 0.5%) induced corneal endothelial cell edema, even
disappearance [5,8], in vivo toxic effect of BAC on the barrier
function of corneal endothelium remains unclear.
Aqueous humor movements into the cornea are required as a
source of nutrition for cells residing within the corneal stroma. The
corneal stroma has a tendency to swell due to the presence of non-
diffusible, negatively charged molecules such as hydrophilic
glycosaminoglycans. The corneal endothelium is thought to be
solely responsible for the maintenance of stromal deturgescence,
which is prerequisite for corneal transparency [9,10]. In healthy
cornea, the endothelium forms a semi-permeable barrier that
regulates fluid and solute exchange between the nutrient-rich
aqueous humor and avascular corneal stroma, and tight junctions
are an integral component of this barrier [10–12]. The tight
junctions of the corneal endothelium are focally present around
endothelial cells and serve to prevent the movement of aqueous
humor from anterior chamber into corneal stroma. The tight
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brane proteins such as claudin and occludin; membrane-associated
proteins such as zonula occludens (ZO)-1; and actin filaments [11].
ZO-1 plays an important role in maintaining the barrier function
and has been considered a maker of the tight junction in the
corneal endothelium [11,13]. The corneal endothelium, similar to
the epithelium, exhibits a thick band of actin cytoskeleton at the
apical junctional complex (AJC), which has been referred to as the
peri-junctional actomyosin ring (PAMR). This pool of actin
cytoskeleton is structurally and functionally coupled to cytoplasmic
domains of tight junctions and adherens junctions through linker
protein such as ZO-1. It has been demonstrated that PAMR
disruption is implicated in loss of the barrier integrity in the
corneal endothelium [14,15].
In this study, we evaluated the corneal alternations induced by
topical application of BAC in rabbits. We were particularly
interested in investigating the in vivo toxic effect of BAC on the
barrier function of the corneal endothelium.
Methods
Animals and BAC Treatment
A total of 24 male white New Zealand rabbits (obtained from
Shanghai Medical Laboratory Animal Center, Shanghai, China)
weighing between 2 and 2.5 kg were randomly assigned to three
groups of 8 rabbits each. The animals were housed individually in
cages at constant room temperature (19–23uC) and humidity of
40%–50% with a constant 12-hour light-dark cycle. They were fed
with chow and water ad libitum. Different concentration of BAC-
0.01%, 0.05%, or 0.1% (Sigma, St. Louis, MO) was applied to one
eye of each rabbit twice daily (8 AM and 5 PM) for 4 days, with
the second eye of each animal serving as a BAC-free control. All
the experimental and animal care procedures were performed in
compliance with the ARVO Statement for the Use of Animal in
Ophthalmic and Vision Research and approved by the animal
ethics committee of Xiamen University School of Medicine
(approval ID: XMUMC 2009-01-18).
Aqueous Tear Production
Rabbits were injected intraperitoneally with a mixture of
xylazine (1 mg/kg body weight; Bayer, Shawnee Mission, KS)
and sodium pentobarbital (20 mg/kg; Abbott Laboratories, North
Chicago, IL) to keep the animals immobile. Five minutes after
topical application of proparacaine (Alcaine; Alcon, Fort Worth,
TX), tear production was measured with Schirmer paper strip
(Tianjin Jingming New Technology Development Co., Ltd.,
Tianjin, China). The Schirmer paper strip was inserted into the
lower conjunctival fornix and left in place for 5 minutes. After the
strip was removed, the amount of wetting in millimeter was
recorded to an accuracy of 0.5 mm.
Slit-lamp Evaluation and Fluorescein Test
The ocular surface was evaluated using a slit-lamp biomicro-
scope (BQ900H Haag-Streit, Bern, Switzerland). Two microliters
of 1% sodium fluorescein was dropped into the conjunctival sac,
and the excess fluorescein was washed out with saline. Cornea was
examined and graded under the slit-lamp biomicroscope with a
cobalt blue filter [16].
In Vivo Confocal Microscopy
After fluorescein staining analysis, a laser scanning confocal
microscopy (Heidelberg Retina Tomography (HRTIII)/Rostock
Corneal Module [RCM]; Heidelberg Engineering GmbH,
Dossenhein, Germany) was used to examine corneas in vivo.
The use of this microscope has been described previously [17]. A
drop of carbomer gel (Alcon Laboratories, Fort Worth, TX) was
applied as coupling medium between the applanating lens and the
cornea. A diode laser is used as a light source with a wavelength of
670-nm. The objective of the microscope is immersion lens
(Olympus, Hamburg, Germany), magnification 6 60, which is
covered by a polymethyl methacrylate cap. Images consist of 384
6384 pixels, allowing a scanning area of 400 mm
2 with lateral and
vertical resolutions of both 1 mm and a magnification up to 800
times. The center of the cap was applanated onto the central
cornea by adjusting the controller, and in vivo digital images of
the cornea were visualized directly on the computer screen. The
central cornea was examined and more than 10 images were
taken for each of the following structure: superficial and basal
epithelium, stroma, and endothelium. The mean central corneal
thickness was calculated based on the depth difference between the
most superficial epithelium and the endothelium and was recorded
as the average of a minimum of three individual acquisitions. All
measurements were performed by a single investigator masked to
the specific experimental conditions. At the end, the epithelial cell
size, epithelial basal cell and endothelial cell density were
automatically calculated using the tomography-associated soft-
ware. Cell density was recorded as cells per square millimeter.
Based on 10 images, the means and standard deviations were
calculated for each parameter.
Measurement of Permeability to Carboxy Fluorescein
(CF)
Corneal epithelial barrier function was evaluated on the basis
of measurement of corneal permeability to CF (0.3%, Cohasset,
MA). The fluorophotometric methods were modified for rabbits
from a previous report in rat [18]. In brief, 10 minutes after 40 mL
of CF was applied to each ocular surface, the animals (n=3 per
group) were euthanized with overdose of pentobarbital sodium
and cornea were excised. Each cornea was washed 3 times in 1mL
of balanced salt solution (BBS; Alcon Laboratories, Fort Worth,
TX) for 5 minutes per wash, and places in a tube with a tube with
1mL BBS. Each tube was wrapped in aluminum foil to protect the
solution from light and placed on an orbital shaker for 90 minutes.
The concentration of CF (nmol/mL) was measured by using a
Gilfrod Fluoro IV fluormeter (Corning, Oberlin, OH).
Under a surgical microscopy, aqueous humor (0.1ml) was
removed from the anterior chamber with 33G NanoFil Injectior
System (World Precision Instruments, Sarasota, FL, USA) through
the lateral corneal limbus. Twenty minutes after 0.1 mL of CF was
injected into the anterior chamber, the animals (n=3 per group)
were euthanized. The corneas were excised, and endothelial
permeability to CF was measured as described above.
Immunofluorescein Staining
After in vivo examinations, rabbits (n=5 per group) were
euthanized after intravenous injection of a lethal dose of pen-
tobarbital sodium. The eyes (including bulbar conjunctiva) were
enucleated, and the nasal and temporal bulbar conjunctivas were
snap-frozen in liquid nitrogen and cut into 8-mm -thick sections.
Sections were fixed in acetone for 10 minutes at 4uC. After
washing in phosphate-buffer saline (PBS), the sections were
incubated with 1% bovine serum albumin (BSA) to block
nonspecific binding, and then overlaid with a 1:50 dilution of
mouse anti-rabbit MUC5AC antibody (Abcam, Cambridge, UK)
overnight at 4uC. The second day, the sections were washed with
PBS, incubated with a 1:100 dilution of fluorescein isothiocyanate
(FICT)-conjugated goat anti-mouse IgG (Cell Signaling Technol-
ogy, Inc., Danvers, MA) for 1 hour at 4uC, followed by three
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Hoechst 33342 dye (Sigma).
Under a dissecting microscope (Model SZ40; Olympus, Tokyo,
Japan), the retina, lens, and iris were discarded and four incisions
were made in each cornea. Each cornea was fixed in situ in PBS
with 4% paraformaldehyde for 5 minutes, and then was
permeabilized with acetone for 3 minutes at -20uC. Subsequently,
the corneas were washed in PBS with 1% Triton X-100 and 1%
dimethyl sulfoxide (DMSO; TD buffer) as described previously
[19,20]. To block nonspecific staining, tissue blocks were incubated
in 1% BSA diluted in TD buffer for 1 hour. Then, the tissues were
placed in 1:100 of mouse anti-rabbit ZO-1 antibody (Zymed,
Carlsbad, CA) for 8 hours with agitation at 4uC. Next, the tissues
were washed with TD buffer, placed in Alexa Fluor 488-conjugated
secondary antibody (1:500 dilution; Molecular Probes; Eugene,
OR) for 1 hour at 4uC. After distilled water wash, the whole-mount
cornea tissues were mounted endothelial side up on a slide and
stained with a nuclear fluorescence dye, 4,6-diamidino-2-pheny-
lindole (DAPI, Vector, Laboratories, Burlingame CA).
For PAMR staining, the whole mount corneas were incubated
in 1:1000 of Texas-red conjugated phalloidin (Molecular Prbes,
Eugene, OR) overnight with agitation for 4 hours at 4uC. The
tissues were rinsed three times in PBS (5 minutes per rinse), and
then the whole mount corneas were mount epithelial or
endothelial side up on a slide and stained with DAPI. The tissues
and sections were all examined with a laser confocal microscopy
(Olympus Fluoview 1000; Olympus, Japan).
Statistical Analysis
Quantitative data are presented as mean 6 SD and were
analyzed by Dunnett multiple comparison test. P,0.05 was
considered statistically significant.
Results
Aqueous Tear Production and Fluorescence Staining
There was no statistically difference between the BAC-treated
and control eyes in aqueous tear production (P.0.1) (Fig. 1A). In
addition, no substantial fluorescein staining was detected in the
eyes treated with BAC, even at the highest concentration (Fig.1F).
In Vivo Confocal Microscopy Analysis
The corneal superficial epithelial cells of control rabbits had a
polygonal mosaic appearance with brightly reflective nuclei
Figure 1. Toxic effects of BAC on aqueous tear production and conjunctival MUC5AC staining cell density. (A)Schirmer test. (B)
conjunctival MUC5AC staining cell density. Representative images of immunofluorescence staining on conjunctival cryosections showing MUC5AC
staining (green) with DAPI as nuclear counterstaining (blue). (C) Control group. (D) 0.1% BAC treated group. Representative images of corneal
fluorescein staining showing no substantial fluorescein staining was apparent in both control (E) and 0.1% BAC treated (F) eyes. There were no
statistically significant differences between the BAC-treated and the control groups in aqueous tear production and conjunctival MUC5AC staning cell
density 4 days after BAC treatment (Dunnett test). Data show mean 6 SD of values from 4 eyes per group.
doi:10.1371/journal.pone.0026103.g001
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abnormalities of the corneal superficial epithelial cells, including
partial desquamation of epithelial cells, irregular cells shapes,
anisocytosis and loss cell borders, abnormal reflectivity patterns,
swollen (Fig.2B-D). Superficial epithelial cells were clearly
observed in the eyes treated with 0.1% BAC, and the size of
these cells was significantly larger, by 93.7%, than that of control
eyes (Fig. 2E). These larger cells had a brightly reflective round
mosaic appearance with dark nuclei (Fig. 2D).
The control basal epithelial cells appear as regular mosaic of
dark cell bodies with light, narrow inter-cellular borders (Fig. 3A).
The 0.01% BAC treatment did not induce any inflammatory cell
infiltration in the epithelial basal layer, but the density of basal cells
was significantly decreased, compared with those of normal and
higher BAC concentration eyes (Fig. 3B, 3E). The 0.05% and
0.1% BAC induced inflammatory cell infiltration in the basal
epithelium. The inflammatory cells were counted, giving densities
of 560.3628.3 and 368.2616.5 cells/mm
2 in the eyes treated with
0.05% BAC and 0.1% BAC, respectively. At both of the
concentrations, the number of basal cells was significantly higher
than that of control (Fig. 3C-E).
In control anterior stroma, keratocyte nuclei were seen as bright
objects against a dark background. Hyperreflective membrane
bridge-like structures (,0.5 mm diameter) were occasionally
observed, and some of these structures formed distinct intercellular
bridge between two or more cells (Fig 4A, arrow). These highly
distinctive intercellular membrane bridge-like structures were
generally short and straight and largely resemble membrane
nanotubes observed in the mouse cornea.
21 The abundance of
these structures was significantly increased from 10.161.1 per
square millimeter in the control to 160615.8 per square
millimeter in the corneas treated with 0.01% BAC, suggesting
that they play an important role in vivo in cell-cell communication
during the BAC-induced inflammation (Fig. 4B, 4E). The 0.05%
and 0.1% BAC induced whole stromal disorganization, with loss
of normal cell borders. The numbers of membrane bridge-like
structures in both groups were decreased compared with 0.01%
BAC treated rabbits, and yet still significantly higher than in the
control (Fig. 4C-E).
The control endothelial cells had a polygonal mosaic appear-
ance, with some larger hexagonal cells also apparent (Fig. 5A).
Application of 0.01% and 0.05% BAC seemed not to inflict
significant damage on the endothelial cells (Fig.5B, 5C). However,
0.1% BAC treated rabbits exhibited significant abnormal
endothelial change, with presence of hyporeflective spots at many
cell-cell borders (Fig. 5D, arrow). Cell density in the endothelium
was not significantly affected by BAC treatment (Fig. 5E).
We also measured central corneal thickness in the BAC-treated
and control eyes. In control eyes, the mean central cornea
thickness was 35566 mm. Central corneal thicknesses was
significantly increased by 57.2% in eyes that received 0.1%
BAC, but BAC at lower concentration did not induce significant
change in mean corneal thickness (Fig. 6A). These data thus
suggested that higher BAC concentration leads to corneal edema
as a result of a loss of corneal endothelial barrier function.
Permeability Measurement
As shown in Figure 6B, treatment with BAC significantly
increases epithelial permeability, compared with untreated
control. Endothelial permeabilities measured for control versus
0.1% BAC treated corneas equaled 16 6 5.2 nmol/mL and 125 6
14.7 nmol/mL. These values were significantly different
(P,0.001). In contrast, there was no significant difference of
endothelial CF uptake between control and lower BAC concen-
tration treated corneas (Fig. 6C).
Immunofluorescence Staining Analysis
Immunofluorescence staining of conjunctival tissues with
MUC5AC antibody revealed that MUC5AC positive cells were
located in the nasal and temporal bulbar conjunctivas of BAC-
treated and control eyes (Fig. 1C, 1D). Statistical analysis showed
no significant difference between the BAC-treated and control
eyes in the density of conjunctival MUC5AC positive cells
(Fig. 1B).
We next examined the effect of BAC on the expression of ZO-1
in the corneal epithelium. In the control corneas, ZO-1 is localized
contiguously at the superficial cell-cell boundaries and accordingly
stained uniformly at the cell borders (Fig. 7A). In contrast, ZO-1
staining was patchy and discontinuous in eyes treated with BAC
(Fig. 7B-D). These observations thus suggested that BAC induced
disruption of the localization of ZO-1 and loss of superficial cells in
many areas of the epithelium.
To further corroborate presence of significant damage on the
endothelial cell-cell borders, as revealed by in vivo confocal
microscopy, we next examined the organization of the AJC. As
shown by confocal images in Figure 8, a continuous linear pattern
of ZO-1 staining at the boundaries of adjacent endothelial cells
was found in the control eyes (Fig. 8). In both the 0.01% and
0.05% BAC-treated eyes, the pattern of ZO-1 distribution is
Figure 2. Toxic effect of BAC on the morphology of rabbit corneal epithelial superficial cells. Representative in vivo confocal images of
the corneal epithelium in different groups. (A) Untreated control. (B) 0.01% BAC. (C) 0.05% BAC. (D) 0.1% BAC. Mean cell size at the epithelial surface
was shown in (E). Note that the size of surface cells in the corneal epithelium of eyes treated with 0.1% BAC was significantly larger than that of
control eyes. Data are mean 6 SD of values from eight eyes per group. ** P,0.01 (Dunnett test).
doi:10.1371/journal.pone.0026103.g002
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distribution of ZO-1 at intercellular border was found to be
retracted and dislocation from the cell-cell border in eyes treated
by 0.1% BAC, as evidenced by discontinuities in ZO-1 localization
(Fig. 8B, arrow). These observations thus suggested that high BAC
concentration could disrupt the TJs in the rabbit corneal
endothelium in vivo.
We also investigated remodeling of the PAMR in response to
BAC in vivo. PAMR is formed by the actin cytoskeleton at the
AJC, and is structurally and functionally coupled to cytoplas-
mic domains of TJs and AJs.
11 In control and BAC at low
concentration treated eyes; F-actin formed a characteristic dense
bend of PAMR (Fig 8C). In contrast, PAMR compacted into a
contractile ring in 0.1% BAC treated eyes (Figure. 8D).
Discussion
BAC is the most frequently used preservative in multi-dose eyes
drops for its apparently good safety/efficacy profile. However, the
generally good bactericidal outcomes have tended to overshadow
the significant number of patients who undergo ocular discomfort
after long-term use. Therefore, prophylaxis and treatment of toxic
reactions associated with BAC have become important clinical
issues. In the present study, we utilized an animal model to
examine the toxic effect of BAC on the whole cornea. Our choice
of different concentrations of BAC in this experiment was based
on clinical practice and previous experimental studies. BAC is
most often used in ophthalmic preparations at a concentration of
0.01% [4]. BAC at 0.1% was found to cause corneal edema [6]
and was used to develop a rabbit dry eye model [21]. The 0.05%
BAC concentration was added in this set of experiments, so as to
better characterize the changes in the cornea found between the
0.01% and the 0.1% BAC concentrations.
We have now shown that topical application of BAC, even at a
low concentration, breaks down rabbit corneal epithelial barrier
function, as revealed by measurement of permeability to CF. ZO-
1, which is a marker of tight junction of corneal epithelium, is
contiguous at superficial cell-cell border [22,23], and its dislocation
Figure 3. Toxic effects of BAC on the morphology of rabbit corneal epithelial basal layer. Representative in vivo confocal images of the
corneal epithelium in different groups. (A) Untreated control. (B) 0.01% BAC. (C) 0.05% BAC. (D) 0.1% BAC. Mean basal cell and inflammatory cell
densities were shown in (E) and (F), respectively. Data are mean 6 SD of values from eight eyes per group. ** P,0.01 (Dunnett test).
doi:10.1371/journal.pone.0026103.g003
Figure 4. Toxic effects of BAC on the morphology of rabbit corneal anterior stroma. Representative in vivo confocal images of corneal
anterior stroma in different groups. (A) Untreated control. (B) 0.01% BAC. (C) 0.05% BAC. (D) 0.1% BAC. Mean membrane bridge-like structure (A,
arrow) was shown in (E). Note the dramatic difference in membrane bridge-like structure between control and BAC-treated eyes. Data are mean 6 SD
of values from eight eyes per group. ** P,0.01, *** P,0.001 (Dunnett test).
doi:10.1371/journal.pone.0026103.g004
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study, we found that in control eyes, ZO-1 distribution was
contiguous at the cell-cell borders at the surface of the rabbit
corneal epithelium. In contrast, in BAC treated corneas, ZO-1
immunoreactivity was patchy and discontinuous in the superficial
epithelium. Recent studies have proven that exposure to BAC
induce a continuous decline in corneal transepithelial electric
resistance in rabbit [26,27]. Our study extends these finding and
confirms that topical application of BAC disrupt the tight junctions
between superficial cells in the rabbit corneal epithelium in vivo.
We found that the highest BAC concentration used here (0.1%)
not only resulted in a significant increase in the size of cells at the
surface of the corneal epithelium, but also induced maximum
corneal surface barrier damage, as shown by the severe CF uptake.
These findings suggest that BAC at high concentration causes
corneal surface epithelial cell edema and more adversely affect the
barrier integrity of the corneal epithelium.
Our results showed a dose-response relationship for BAC-
treated corneal epithelial basal layer, with low (0.01%) BAC
concentration inducing basal cell edema, whereas the high
(0.05% and 0.1%) BAC concentrations caused inflammation and
increase in cell density. Liang et al reported that topical repeated
application of BAC induced important inflammatory cell infiltra-
tion in rabbit corneal epithelial basal layer and stroma [7]. In
3D-reconstituted corneal epithelium, Pauly et al found that the
number of proliferative cells increased after BAC treatment [28].
Our results were consistent with these studies, showing that topical
application of BAC quickly impairs the corneal epithelium.
Membrane nanotubes that connect two or more cells have been
found in vitro in a number of cells types including rat
pheochromocytoma cell lines, normal rat kidney cells [29], and
primary cultures of dendritic cells (DCs), macrophages, human
peripheral blood NK cells, and B cells [30]. Recently, long and
fine (,0.8 mm in diameter) membrane nanotube-like structures on
bone marrow-derived major histocompatibility (MHC) class II+
DCs have been documented in the corneal stroma of normal
mouse. The frequency of these nanotubes was significantly
increased in corneas subjected to trauma and LPS, suggesting
that these structures play an important role in vivo in cell-cell
communication between widely spaced dendritic cells during
inflammation [31]. Using in vivo confocal microscopy, we found
that a few of long and hypereflective membrane bridge-like
structures (,0.5 mm in diameter) were distributed in normal
corneal anterior stroma. Four days after application of 0.01%
BAC, the number of membrane bridge-like structures in anterior
central stroma increased from 10.161.1 per square millimeter to
160615.8 per square millimeter. Such a rapid and significant
modulation ofmembranebridge-likestructures density suggests that
they serve as critical structures in BAC at low concentration
inducing corneal pathological changes. We found that the density of
Figure 5. Toxic effects of BAC on the morphology of the rabbit corneal endothelium. Representative in vivo confocal microscopic images
of the corneal endothelium in different groups. (A) Untreated control. (B) 0.01% BAC. (C) 0.05% BAC. (D) 0.1% BAC. There was no significant difference
between BAC at lower concentrations treated and control eyes in the endothelial morphology. However, in eyes treated with 0.1% BAC, a number of
hyporeflective spots were present at endothelial cell-cell borders (D, arrow). The mean endothelial cell density did not reach statistically significant
levels in eyes treated with BAC when compared with control eyes (E). Data are mean 6 SD of values from eight eyes per group.
doi:10.1371/journal.pone.0026103.g005
Figure 6. Toxic effects of BAC on central corneal thickness and CF uptake in the rabbit. (A) Central corneal thickness. (B) Epithelial CF
uptake. (C) Endothelial CF uptake. Note that epithelial CF uptake was significantly increased in all BAC treated corneas, whereas central corneal
thickness and endothelial CF uptake were only significantly increased in eyes treated with 0.1% BAC compared with those in control eyes. Data are
mean 6 SD of values from eight eyes per group. ** P,0.01, *** P,0.01 (Dunnett test).
doi:10.1371/journal.pone.0026103.g006
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and 0.1% BAC, probably because high concentration primarily
caused deep tissue damage. To our knowledge, we are the first
group to report the existence of the long and hypereflective
membranebridge-likestructures inthecentralcorneal stromaofthe
rabbit eye. Further studies are needed to determine whether the
structures were membrane nanotubes that express MHC class II
antigen.
Xiong et al. have reported significant decreases in Schirmer
score and goblet cell density and increase in fluorescein scores in
rabbits after 7 days treatment of 0.1% BAC twice daily [21]. They
suggested that topical application of 0.1% BAC can induce a
rabbit dry eye model, which is suitable for studying human dry eye
syndrome. In the present study, we have found significant whole
corneal defect without significant changes in aqueous tear
production and corneal fluorescein scores after exposure to 0.1%
BAC for 4 days. We noted that there was no significant difference
of the number of MUC5AC cells between BAC-treated and
control eyes. We also noted that even lower concentration of BAC
could induce significant corneal stromal alterations. Our results,
taken together, indicate that the rabbit cornea is very sensitive to
the toxicity of BAC. Therefore, the direct toxic effect on the whole
cornea should be taken into account if BAC is used to establish an
animal dry eye model.
Pauly et al. performed a series of toxicological assessments in the
rat eye after instillations of BAC [8]. They found that BAC at low
concentrations (0.01% and 0.1%) induced damage restricted to the
the epithelium, whereas the highest concentrations (0.25% and
0.5%) caused epithelial denudation as well as major stromal and
endothelial damage. In our study, in vivo confocal microscopy
revealed destructuring of the corneal stroma with presence of a lot
of membrane bridge-like structures in eyes treated by lower
(0.01% and 0.05%) concentration of BAC. Moreover, 0.1% BAC
induced significant corneal endothelial cell defects. The reason
for these discrepancies is not immediately clear; one possible
explanation is due to species differences.
An important function of the corneal endothelium is to provide
a barrier to the aqueous humor movements. The tight junction
plays an important role in the establishment and maintenance of
the barrier function of the endothelium [32,33]. The tight
junctions of corneal endothelium can be disrupted as a result of
aging, inflammatory reaction, iatrogenic injury, and genetic
disorders such as Fuch’s dystrophy [34]. Our data suggest that
topical application of high BAC concentration can induce loss of
barrier integrity in the rabbit corneal endothelium in vivo. There
are several lines of evidence to support this notion: First,
application of 0.1% BAC, but not that of lower BAC
concentrations, resulted in significant increases in central corneal
thickness and endothelial permeability, compared with those in
control eyes (P,0.01). This finding means that high BAC
concentration can lead to significant corneal edema as a result
of a loss of corneal barrier function. Second, in vivo confocal
microscopy revealed presence of hyporeflective spots at many
endothelial cell-cell borders in 0.1% BAC treated eyes, indicating
that high BAC concentration inflict significant damage on the
endothelial cell junctions. Third, in control and low concentrations
of BAC-treated eyes, ZO-1 expression exhibited a continuous
linear pattern of at cell-cell boundaries in the endothelium,
whereas in eyes treat with 0.1% BAC, ZO-1 immunoreactivity was
discontinuous, indicating the disruption of tight junctions.
Moreover, 0.1% BAC induced the compaction of PAMR into a
contractile ring. Taken together, the present study clearly shows
that topical application of high concentration of BAC can not only
damage the corneal epithelium and stroma, but also break down
the barrier integrity in the rabbit corneal endothelium in vivo.
In summary, our study demonstrated that topical application of
BAC can quickly impair the whole cornea without occurrence of
dry eye. BAC at high concentration induces disruption of the
barrier integrity in the corneal endothelium. These findings may
Figure 7. Toxic effects of BAC on localization of ZO-1 in the
rabbit corneal epithelium. Corneal tissue blocks prepared from a
control eye (A) or from eyes treated with 0.01% (B), 0.05% (C) or 0.1%
BAC (D). ZO-1 staining was observed as a continuous linear pattern
along with superficial cell-cell borders in normal rabbit corneal
epithelial cells. In contrast, ZO-1 staining was patchy and discontinuous
in eyes treated with BAC (B, C, and D). Note that BAC induced
disappearance of ZO-1 in a concentration-dependent manner.
doi:10.1371/journal.pone.0026103.g007
Figure 8. Toxic effects of BAC on the PAMR and distribution of
ZO-1 in the corneal endothelium. (A, C) Untreated control eyes. (B,
D) 0.1% BAC treated eyes. In untreated eyes, ZO-1 distribution is
contiguous at the endothelial cell-cell border (A) and the characteristic
organization of cortical actin with intact PAMP is observed (C). In
contrast, BAC at 0.1% induced the dispersion of ZO-1(B), as evidence by
discontinuities in ZO-1 distribution (C, arrow) and the disruption of
PAMR (D).
doi:10.1371/journal.pone.0026103.g008
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effect of BAC on the cornea.
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